Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis.
OBJECTIVE
To identify recent papers showing how human and parasite genetics influence leishmaniasis, and how understanding of the immunopathology may be utilized in immunotherapy for these diseases.


RESULTS
Progress has been made in recent years showing the complexity within populations of Leishmania spp. and indicating that different strains lead to diverse clinical pictures and responses to treatment. Thus detection of parasite genetic tags for the precise identification of infecting strains, and for predictive diagnosis of clinical and therapeutic fates seems now possible. Host genetic loci involved in disease outcome have been detected, which may also be explored for better case management. These developments in diagnosis will demand expanding the therapeutic arsenal to take their expected effect. This is starting to be fulfilled by immunotherapies successfully employed to treat cases refractory to standard first line drugs, as the result of a more profound comprehension of the immunopathology of the leishmaniases.


CONCLUSIONS
The knowledge mounting has already helped explain why different patients present different forms of leishmaniasis and respond differently to treatment, and may be on the verge of catalyzing a major change in the already over a century old paradigm of diagnosing and managing these patients.
Schriefer
Albert
A
Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Federal Unviersity of Bahia, Salvador, Bahia, Brazil.
Wilson
Mary E
ME
Carvalho
Edgar M
EM
D000818:Animals; D006801:Humans; D007167:Immunotherapy; D007891:Leishmania / Q000235:genetics / Q000472:pathogenicity / Q000502:physiology; D007896:Leishmaniasis / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D054332:Leishmaniasis Vaccines; D016052:Protozoan Vaccines / Q000276:immunology
D054332:Leishmaniasis Vaccines; D016052:Protozoan Vaccines